Biologics for Psoriasis
Biologic treatments for psoriasis can help clear your skin and ease symptoms, but there are some risk factors to consider. Here’s what you need to know. (Source: WebMD Health)
Source: WebMD Health - October 24, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Psoriasis Patients Who Meditate May Ease Symptoms, Improve QOL
Review suggests mindfulness and meditation may offer benefit as adjunct therapy for moderate - to - severe plaque psoriasis (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - October 21, 2022 Category: Psychiatry Tags: Dermatology, Family Medicine, Internal Medicine, Psychiatry, Journal, Source Type: news
Psoriasis Patients Who Meditate May Ease Symptoms, Improve QOL
FRIDAY, Oct. 21, 2022 -- Meditation may help patients manage psoriasis, according to a review published online Sept. 14 in Dermatology and Therapy.
Erin Bartholomew, from University of California, San Francisco, and colleagues conducted a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2022 Category: Pharmaceuticals Source Type: news
Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: a cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) - Yeroushalmi S, Chung M, Bartholomew E, Hakimi M, Koo J.
To the Editor: Biologics are highly efficacious biologic for treating moderate-to-severe plaque psoriasis, particularly brodalumab. However, the use of brodalumab has been severely limited due to a black box warning and an associated Risk Evaluation and Mi... (Source: SafetyLit)
Source: SafetyLit - October 20, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Psoriasis Flakes: How To Deal With The Mess
Have psoriasis flakes settled on your carpet, car seats, and clothes? Learn a few quick and easy ways to clean them up. (Source: WebMD Health)
Source: WebMD Health - October 19, 2022 Category: Consumer Health News Source Type: news
Psoriasis: Getting Comfortable in My Skin
How do you find psoriasis treatments and remedies that work for you? Learn how four women treat their psoriasis and control skin flares. (Source: WebMD Health)
Source: WebMD Health - October 19, 2022 Category: Consumer Health News Source Type: news
Comorbidity Burden Higher in Generalized Pustular Psoriasis
WEDNESDAY, Oct. 19, 2022 -- Patients with generalized pustular psoriasis (GPP) have increased comorbidity compared with the general population and with patients with psoriasis vulgaris (PV), according to a study published online Oct. 11 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Expert shares the best 'anti-inflammatory' diet to curb symptoms of psoriasis
Certified nutritionist Rebekah Lamb spoke to Express.co.uk about the best "anti-inflammatory" diet to curb symptomatic psoriasis. (Source: Daily Express - Health)
Source: Daily Express - Health - October 16, 2022 Category: Consumer Health News Source Type: news
Why Some Psoriatic Disease Symptoms Are Unreported
Why do symptoms of psoriasis, psoriatic arthritis, and psoriatic disease get missed? Find out from a psoriatic disease advocate. (Source: WebMD Health)
Source: WebMD Health - October 10, 2022 Category: Consumer Health News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Severe and Rare Infections Among Adults With Psoriasis Severe and Rare Infections Among Adults With Psoriasis
This study found that as the severity of psoriasis increases, so does the risk of severe and rare infections.The British Journal of Dermatology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 7, 2022 Category: Infectious Diseases Tags: Dermatology Journal Article Source Type: news
Apremilast May Offer Cardiometabolic Benefit in Psoriasis Patients
TUESDAY, Oct. 4, 2022 -- For patients with moderate-to-severe psoriasis, apremilast appears to have a neutral association with aortic vascular inflammation, generally beneficial associations with certain cardiometabolic biomarkers, and associations... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2022 Category: Pharmaceuticals Source Type: news
